Search details
1.
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
N Engl J Med
; 386(16): 1519-1531, 2022 04 21.
Article
in English
| MEDLINE | ID: mdl-35443108
2.
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Blood
; 131(24): 2661-2669, 2018 06 14.
Article
in English
| MEDLINE | ID: mdl-29724899
3.
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Blood
; 128(7): 971-81, 2016 08 18.
Article
in English
| MEDLINE | ID: mdl-27335278
4.
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Blood
; 121(13): 2533-41, 2013 Mar 28.
Article
in English
| MEDLINE | ID: mdl-23361907
5.
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Blood
; 122(6): 1017-25, 2013 Aug 08.
Article
in English
| MEDLINE | ID: mdl-23801631
6.
DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells.
J Pharmacol Exp Ther
; 350(3): 646-56, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-24993360
7.
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Biopharm Drug Dispos
; 35(4): 237-52, 2014 May.
Article
in English
| MEDLINE | ID: mdl-24415392
8.
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.
Haematologica
; 100(5): e190-3, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25596271
9.
Expression of Concern to: Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition.
J Hematol Oncol
; 12(1): 116, 2019 11 22.
Article
in English
| MEDLINE | ID: mdl-31753040
10.
Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition.
J Hematol Oncol
; 12(1): 11, 2019 01 25.
Article
in English
| MEDLINE | ID: mdl-30683135
11.
Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy.
Clin Cancer Res
; 25(7): 2064-2071, 2019 04 01.
Article
in English
| MEDLINE | ID: mdl-30642912
12.
Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia.
Mol Cancer Ther
; 16(8): 1669-1679, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28428443
13.
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
J Clin Invest
; 126(4): 1438-50, 2016 Apr 01.
Article
in English
| MEDLINE | ID: mdl-26927674
14.
Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
J Control Release
; 220(Pt B): 758-65, 2015 Dec 28.
Article
in English
| MEDLINE | ID: mdl-26385168
15.
Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.
Chem Biol Drug Des
; 80(6): 971-80, 2012 Dec.
Article
in English
| MEDLINE | ID: mdl-22978415
16.
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Cancer Cell
; 20(1): 53-65, 2011 Jul 12.
Article
in English
| MEDLINE | ID: mdl-21741596
Results
1 -
16
de 16
1
Next >
>>